title: Brentuximab in the treatment of CD30-positive enteropathy-associated T-cell lymphoma.
abstract: Enteropathy-associated T-cell lymphoma (EATL) is a rare aggressive lymphoma that confers a poor prognosis with current treatment strategies. Given the rarity of this disease, prospective randomized trials are limited, and thus a standard validated treatment strategy is lacking. This report presents the disease course of a patient with EATL who was treated with single-agent brentuximab vedotin, an anti-CD30 conjugated antibody.
authors: Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
authors: Waleed F
authors: WF
authors: Khalaf
authors: Meghan E
authors: ME
authors: Caldwell
authors: Nishitha
authors: N
authors: Reddy
mesh_terms: D000906:Antibodies / Q000276:immunology; D000079963:Brentuximab Vedotin; D058527:Enteropathy-Associated T-Cell Lymphoma / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000276:immunology*; D008297:Male; D008875:Middle Aged
chemical_list: D000906:Antibodies; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin